Your browser doesn't support javascript.
loading
Derivation and Validation of a Clinical Risk Assessment Model for Cancer-Associated Thrombosis in Two Unique US Health Care Systems.
Li, Ang; La, Jennifer; May, Sarah B; Guffey, Danielle; da Costa, Wilson L; Amos, Christopher I; Bandyo, Raka; Milner, Emily M; Kurian, Karen M; Chen, Daniel C R; Do, Nhan V; Granada, Carolina; Riaz, Nimrah; Brophy, Mary T; Chitalia, Vipul; Gaziano, J Michael; Garcia, David A; Carrier, Marc; Flowers, Christopher R; Zakai, Neil A; Fillmore, Nathanael R.
Affiliation
  • Li A; Section of Hematology-Oncology, Baylor College of Medicine, Houston, TX.
  • La J; Massachusetts Veterans Epidemiology Research and Information Center, VA Boston Healthcare System, Boston, MA.
  • May SB; Institute for Clinical & Translational Research, Baylor College of Medicine, Houston, TX.
  • Guffey D; Institute for Clinical & Translational Research, Baylor College of Medicine, Houston, TX.
  • da Costa WL; Section of Epidemiology and Population Science, Baylor College of Medicine, Houston, TX.
  • Amos CI; Institute for Clinical & Translational Research, Baylor College of Medicine, Houston, TX.
  • Bandyo R; Section of Epidemiology and Population Science, Baylor College of Medicine, Houston, TX.
  • Milner EM; Harris Health System, Houston, TX.
  • Kurian KM; School of Medicine, Baylor College of Medicine, Houston, TX.
  • Chen DCR; School of Medicine, Baylor College of Medicine, Houston, TX.
  • Do NV; Massachusetts Veterans Epidemiology Research and Information Center, VA Boston Healthcare System, Boston, MA.
  • Granada C; Section of General Internal Medicine, Boston University School of Medicine, Boston, MA.
  • Riaz N; Massachusetts Veterans Epidemiology Research and Information Center, VA Boston Healthcare System, Boston, MA.
  • Brophy MT; Section of General Internal Medicine, Boston University School of Medicine, Boston, MA.
  • Chitalia V; Section of Hematology-Oncology, Baylor College of Medicine, Houston, TX.
  • Gaziano JM; Section of Hematology-Oncology, Baylor College of Medicine, Houston, TX.
  • Garcia DA; Massachusetts Veterans Epidemiology Research and Information Center, VA Boston Healthcare System, Boston, MA.
  • Carrier M; Section of Hematology & Medical Oncology, Boston University School of Medicine, Boston, MA.
  • Flowers CR; Massachusetts Veterans Epidemiology Research and Information Center, VA Boston Healthcare System, Boston, MA.
  • Zakai NA; Renal Section, Department of Medicine, Boston University School of Medicine, Boston, MA.
  • Fillmore NR; Institute of Medical Engineering and Science, Massachusetts Institute of Technology, Cambridge, MA.
J Clin Oncol ; 41(16): 2926-2938, 2023 06 01.
Article in En | MEDLINE | ID: mdl-36626707
ABSTRACT

PURPOSE:

Venous thromboembolism (VTE), especially pulmonary embolism (PE) and lower extremity deep vein thrombosis (LE-DVT), is a serious and potentially preventable complication for patients with cancer undergoing systemic therapy.

METHODS:

Using retrospective data from patients diagnosed with incident cancer from 2011-2020, we derived a parsimonious risk assessment model (RAM) using least absolute shrinkage and selection operator regression from the Harris Health System (HHS, n = 9,769) and externally validated it using the Veterans Affairs (VA) health care system (n = 79,517). Bootstrapped c statistics and calibration curves were used to assess external model discrimination and fit. Dichotomized risk strata using integer scores were created and compared against the Khorana score (KS).

RESULTS:

Incident VTE and PE/LE-DVT at 6 months occurred in 590 (6.2%) and 437 (4.6%) patients in HHS and 4,027 (5.1%) and 3,331 (4.2%) patients in the VA health care system. Assessed at the time of systemic therapy initiation, the new RAM included components of the KS with the modified cancer subtype, cancer staging, systemic therapy class, history of VTE, history of paralysis/immobility, recent hospitalization, and Asian/Pacific Islander race. The c statistic was 0.71 in HHS and 0.68 in the VA health care system (compared with 0.65 and 0.60, respectively, for KS). Furthermore, the new RAM appropriately reclassified 28% of patients and increased the proportion of VTEs in the high-risk group from 37% to 68% in the validation data set.

CONCLUSION:

The novel RAM stratified patients with cancer into a high-risk group with 8%-10% cumulative incidence of VTE and 7% PE/LE-DVT at 6 months (v 3% and 2%, respectively, in the low-risk group). The model had improved performance over the original KS and doubled the number of VTE events in the high-risk stratum. We encourage additional external validation from prospective studies.[Media see text].
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pulmonary Embolism / Thrombosis / Venous Thrombosis / Venous Thromboembolism / Neoplasms Type of study: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: J Clin Oncol Year: 2023 Document type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pulmonary Embolism / Thrombosis / Venous Thrombosis / Venous Thromboembolism / Neoplasms Type of study: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: J Clin Oncol Year: 2023 Document type: Article
...